ADARRC

About ADARRC

This author has not yet filled in any details.
So far ADARRC has created 12 blog entries.

Giant cell (temporal) arteritis: No laboratory test or physical finding is pathognomic

2021-03-21T11:24:19+04:00

What signs, symptoms, or laboratory values are diagnostic for giant cell (temporal) arteritis? No single laboratory test or physical finding by itself is useful to identify patients with giant cell arteritis (GCA); even the classic hallmarks of GCA were not very predictive. This study was unable to determine whether several findings taken together increase the odds. Even an erythrocyte sedimentation rate (ESR) greater than 100 mm/h only increases the odds of a positive temporal artery biopsy 3-fold, which is in the low range. However, an ESR less than 40 mm/h moderately predicts a negative biopsy. If you suspect [...]

Giant cell (temporal) arteritis: No laboratory test or physical finding is pathognomic2021-03-21T11:24:19+04:00

No benefit to remdesivir, HCQ, lopinavir, or interferon in large WHO trial of adults hospitalized with COVID-19 (Solidarity)

2021-03-21T11:24:48+04:00

Are older antiviral drugs beneficial for adults hospitalized with COVID-19? This large open-label randomized trial found no benefit to remdesivir, interferon, lopinavir, or hydroxychloroquine for adults hospitalized with COVID-19. The only possible benefit was seen with remdesivir in patients who required low-flow or no oxygen, but the absolute benefit, if any, was small. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 interim WHO Solidarity trial results. N Engl J Med. Published online December 2, 2020. doi: 10.1056/NEJMoa2023184.

No benefit to remdesivir, HCQ, lopinavir, or interferon in large WHO trial of adults hospitalized with COVID-19 (Solidarity)2021-03-21T11:24:48+04:00
Go to Top